Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes

The international multicenter CE Mark clinical trial of the HeartMate 3 Left Ventricular Assist System included 50 patients. Thirty-day survival was 98%, bleeding and strokes were observed in 30% and 4%, respectively.